Table 1.
Comparison of baseline characteristics between non-survivors and survivors among patients with SJS-ILD.
| Characteristics | Total | Non-survivors | Survivors | P value |
|---|---|---|---|---|
| Patient number | 62 | 15 | 47 | |
| Age, years | 59.8 ± 11.4 | 66.3 ± 9.9 | 57.7 ± 11.2 | 0.010 |
| Female sex | 52 (83.9) | 13 (86.7) | 39 (83.0) | > 0.999 |
| Ever-smokers | 14 (22.6) | 6 (40) | 8 (17) | 0.082 |
| BMI, kg/m2 | 23.7 ± 3.1 | 23.5 ± 3.2 | 23.7 ± 3.1 | 0.867 |
| C-reactive protein, mg/dL | 1.1 ± 2.5 | 2.4 ± 4.5 | 0.6 ± 1.1 | 0.141 |
| ANA, positive (> 1:40) | 47 (75.8) | 10 (66.7) | 37 (78.7) | 0.342 |
| Anti SS-A/Ro, positive | 48 (77.4) | 7 (46.7) | 41 (87.2) | 0.001 |
| Anti-SS-B/La, positive | 25 (40.3) | 3 (20.0) | 22 (46.8) | 0.065 |
| FVC, % predicted | 68.2 ± 14.6 | 60.1 ± 13.1 | 70.9 ± 14.2 | 0.012 |
| DLCO, % predicted | 58.9 ± 18.8 | 49.3 ± 16.6 | 61.8 ± 18.6 | 0.035 |
| TLC, % predicted | 71.4 ± 14.1 | 62.2 ± 12.8 | 74.0 ± 13.4 | 0.009 |
| 6MWD, meters | 420.0 ± 113.7 | 329.9 ± 123.3 | 440.8 ± 102.0 | 0.007 |
| 6MWT the lowest SpO2, % | 91.9 ± 4.4 | 89.2 ± 4.0 | 92.5 ± 4.3 | 0.042 |
| BAL Neutrophil % | 12.5 ± 17.3 | 23.3 ± 28.8 | 9.2 ± 11.2 | 0.288 |
| BAL Lymphocyte % | 26.4 ± 15.2 | 13.8 ± 10.6 | 29.5 ± 14.7 | 0.021 |
| HRCT patterns | 0.006 | |||
| UIP | 24 (38.7) | 11 (73.3) | 13 (27.7) | |
| Probable UIP | 26 (41.9) | 2 (13.3) | 24 (51.1) | |
| Alternative diagnosis | 12 (19.4) | 2 (13.3) | 10 (21.3) | |
| Treatment with steroid ± IMa | 53 (85.5) | 12 (80) | 41 (87.2) | 0.674 |
Data are presented as mean ± standard deviation or number (%), unless otherwise indicated.
6MWD six-minute walk test distance, 6MWT the lowest SpO2 lowest oxygen saturation during the six-minute walk test, ANA anti-nuclear antibody, BAL bronchoalveolar lavage, BMI body mass index, DLCO diffusing capacity of the lung for carbon monoxide, FVC forced vital capacity, ILD interstitial lung disease, IM immunosuppressants, SJS Sjögren syndrome, TLC total lung capacity.
aThe immunosuppressants included azathioprine (n = 22), cyclosporine (n = 21), mycophenolate mofetil (n = 27), and cyclophosphamide (n = 8).